Skip to main content
. 2022 Mar 8;14:40. doi: 10.1186/s13195-022-00981-1

Fig. 4.

Fig. 4

PET amyloid (florbetapir) change observed in the region targeted by the SonoCloud-1 device (ROI1). SUVRs referenced to a ROI similar to the target ROI but in the opposite hemisphere (ROI2) showed decreases from the baseline of − 6.6% (SD = 7.2%) at 4 months and − 5.7% (SD = 6.2%) at 8 months